-
Blood: Adolescents and adults with congenital immunodeficiency may also benefit from HSCT treatment
Time of Update: 2022-10-25
In summary, the study showed that adolescents and adults with congenital immunodeficiency can also benefit significantly from allogeneic hematopoietic stem cell transplantation, and age is not a risk factor for poor prognosis.
-
Lancet Oncology: Important new discovery! Shen Hongbing/Hu Zhibin of Nanjing Medical University discovered new endogenous indicators of lung cancer risk to optimize the individualized risk stratification of lung cancer
Time of Update: 2022-10-25
Risk of lung cancer based on chimeric chromosome loss and genetic classification in Nanjing lung cancer cohort study (Figure from Lancet Oncology)Compared with non-carriers with chimeric deletion, carriers were represented in NJLCC (odds ratio [OR] 1.
-
Lancet Oncol: efficacy of progressive metastatic castration-resistant prostate cancer with continued application of enzalutamide
Time of Update: 2022-10-25
Patients with a drop in PSA at week 13 and subsequent progression were screened and recruited into phase P2 to receive up to 10 courses of docetaxel + prednisolone, and then randomized (1:1) into two groups to receive oral enzalutamide or placebo.
-
Potential domestic FIC! GC007g officially opened a Phase 2 registrational clinical trial
Time of Update: 2022-10-25
com/ Follow LinkedIn account @GracellBio. Cautionary Statement Regarding Forward-Looking Statements Statements in this press release regarding future expectations, plans, prospects and other non-historical facts may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 。 These statements may, but do not necessarily contain, the following words and corresponding negative forms or similar words: purpose, anticipate, believe, estimate, anticipate, predict, intend, may, prospect, plan, potential, speculate, propose, seek, may, should, will.
-
Pembrolizumab has another 5 years of survival data, defining the OS "ceiling" and pointing to the benefit of the whole population
Time of Update: 2022-10-25
*For medical professionals only, the 5-year OS data of the world's first PD-1+ chemotherapy first-line treatment of advanced NSCLC was releasedThe 2022 European Society of Medical Oncology (ESMO) Annu
-
NEJM colonoscopy screening test is controversial, is screening necessary? Expert review
Time of Update: 2022-10-25
The results of the world's first colonoscopy multi-center randomized clinical trial were announced, and the screening effect controversy Wei Wenqiang National Cancer Center/National Cancer Clinical Research Center/Cancer Registry Office, Cancer Hospital of the Chinese Academy of Medical Sciences, colorectal cancer is the third most common cancer in the world, It is also the second leading cause of cancer death [1].
-
Mace inventory: 10 classes of 23 anti-tumor drugs that are not limited to cancer
Time of Update: 2022-10-25
According to the results of three clinical trials (NCT02122913, NCR02576431 and NCT02637687) based on the approval, the overall response rate of lalotinib treatment was 75% for patients with NTRK-positive solid tumors, including 22% complete response rate and 53% partial response rate; The duration of response was very long, with a median duration of response of 35.
-
Spring of brain tumor treatment: targeted therapy for the driver gene BRAF has worked!
Time of Update: 2022-10-25
, BRAF V600E-mutant glioblastoma with extracranial metastases responsive to combined BRAF and MEK targeted inhibition: A Case Report, Case Rep Oncol 2022; 15:909-917;Click below to learn more about our clinical trial programsGlioblastoma is a malignant tumor that occurs in the brain and has been lacking a very effective treatment strategy.
-
Nature Genetics: Lin Dongxin/Zheng Jian et al. first revealed that RNA methylation can regulate DNA methylation
Time of Update: 2022-10-25
Recently, Lin Dongxin/Zheng Jian Laboratory of Sun Yat-sen University Cancer Prevention and Treatment Center, together with Professor Chen Jianjun of the Beckman Institute of Hope City National Medical Center, USA, published a research paper titled: RNA m6A regulates transcription via DNA demethylation and chromatin accessibility in the journal Nature Genetics.
-
eClinicalMed: Ramoluzumab has promising efficacy as a second-line treatment for Chinese patients with advanced hepatocellular carcinoma with elevated AFP
Time of Update: 2022-10-25
101679 In a global REACH-2 study, ramucirumab significantly improved overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) compared with placebo.
101679 In a global REACH-2 study, ramucirumab significantly improved overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) compared with placebo.
-
The key to the next cancer therapy breakthrough? One picture to understand the potential targets of recent clinical transformation of cancer
Time of Update: 2022-10-25
Target: FBXO42Disease: Blood cancerJournal/PMID: Science Advances/36129980It was found that dysregulation of the Notch-RBPJ information pathway is responsible for many diseases, including cancer, but how this key pathway is regulated in cells, the modification of related proteins, and the interacting proteins are mostly unknown.
-
Innovation: The application of nanotechnology in tumor immunotherapy
Time of Update: 2022-10-25
Different from traditional cancer immunotherapy, rationally designed nanomaterials can trigger specific tumicidal effects, thereby improving the contact of immune cells to major metastatic sites such as bone, lung and lymph nodes, optimizing antigen presentation, and inducing a long-lasting immune response.
-
Yocardi: The new LNP is targeted to prepare CAR-T in vivo, and the anti-tumor effect is remarkable
Time of Update: 2022-10-25
The researchers used CD3 antibody modified LNP to encapsulate short hairpin RNA (shRNA) containing human interleukin 6 (IL-6) and an integrated plasmid of CAR gene, which can produce CAR-T cells with missing IL-6 secretion function in mice through intravenous injection, and showed an anti-tumor effect comparable to conventional CAR-T treatment in mouse leukemia models, while reducing the release of IL-6 and reducing severeness The occurrence of CRS.
-
J Clin Oncol: Prognosis in non-infantile patients with acute lymphoblastic leukemia with 11q23/KMT2A rearrangement
Time of Update: 2022-10-25
The researchers retrospectively collected data from 629 11q23/KMT2A rearranged ALL patients from 17 members of the Ponte-di-Legno Childhood ALL Working Group and analyzed clinical and biological characteristics, early response to minimal residual lesion assessment at the end of induction therapy (EOI), and the impact of allogeneic hematopoietic stem cell transplantation on prognosis.
-
Express More than 1.7 billion US dollars to help the development of anti-cancer bispecific antibodies! Gilead partners up
Time of Update: 2022-10-25
WuXi AppTec Content Team EditorsWuXi AppTec Content Team EditorsWuXi AppTec Content Team EditorsWuXi AppTec Content Team EditorsWuXi AppTec Content Team EditorsRecently, Gilead Sciences and MacroGenics announced an exclusive licensing and collaboration agreementMacroGenics is a cancer innovative therapy biopharmaceutical company focused on the development and commercialization of monoclonal antibodies and has extensive experience in developing new therapies using its proprietary bispecific antibody development platform, DART.
-
European Radiology: Prediction of preoperative T stage of rectal cancer by a 3D super-resolution MRI radiomics model based on deep learning
Time of Update: 2022-10-25
Original source:Min Hou,Long Zhou,Jihong Sun. Deep-learning-based 3D super-resolution MRI radiomics model: superior predictive performance in preoperative T-staging of rectal cancer.
1007/s00330-022-08952-8Min Hou,Long Zhou,Jihong Sun. Deep-learning-based 3D super-resolution MRI radiomics model: superior predictive performance in preoperative T-staging of rectal cancer.
-
This article summarizes the current status of first-line immunotherapy for non-small cell lung cancer
Time of Update: 2022-10-25
First-line immunomonotherapy1PD-1 inhibitors The KEYNOTE-024 study showed that in patients with advanced NSCLC with PD-L1 expression ≥ 50% and ALK or EGFR negative, the PD-1 inhibitor pembrolizumab had significantly longer progression-free survival (PFS) and overall survival (OS) and fewer adverse events (AEs) compared with platinum-based chemotherapy.
-
Advantages of peripheral blood stem cell transplantation over unrelated donor bone marrow transplantation in the prognosis of adults with acute myeloid leukemia
Time of Update: 2022-10-25
GuideIncluding acute leukemia and malignant lymphoma, allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure patients with hematologic malignancies. When there is no suitable related
-
BioNTech's next battle with Moderna: mRNA oncology vaccines
Time of Update: 2022-10-25
com——List of recent popular events——On October 25, the difficulties of the large-scale production process of exosomes were analyzedOctober 20, 2022 /eMedClub News/--In recent years, the help of new crown vaccines has made mRNA technology more and more mature, Moderna With BioNTech have intensified the layout of mRNA cancer vaccines.
-
The country's first real-world general population colorectal cancer screening prospective clinical results were released, and early screening tests were upgraded
Time of Update: 2022-10-25
Recently, Shenzhen Jinbaihui Biotechnology Co. , Ltd. announced the completion of China's first real-world general population colorectal cancer screening 10,000 prospective clinical trials: "Ruichangt
